The latest episode of the pharmaphorum podcast takes a post-COVID look at the discovery and commercialisation of new vaccines with GlaxoSmithKline’s Philip Cruz.
The company’s vaccines medical director for the UK and Ireland, and a paediatrician by training, Philip talks about the clear pre- and post-COVID differentiation seen in pharma approaches to vaccines.
He also spoke about anti-vaxx misinformation and its effect on vaccine uptake in recent years.
COVID also featured in episode 31, in which Deep Dive editor George Underwood spoke to RedHill biopharma’s chief business officer Guy Goldberg about the potential for new therapeutics to help fight the pandemic.
Guy shared his views on what’s factors have caused COVID-19 treatments to show mixed results so far and his hopes for overcoming some of the key challenges in developing these types of medicines.
He also discusses why COVID therapeutics are still important even after approved vaccines have hit the market – and will continue to be so when the pandemic is over.
You can listen to episode 33 of the pharmaphorum podcast here and episode 31 here, and download the episodes to your computer or find them – and subscribe to the rest of the series – in iTunes, Spotify, acast, Stitcher and Podbean.
Dominic Tyer 